Search Results

Filter
  • 1-10 of  9,882 results for ""Glucagon-Like Peptides""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.

  • Authors : Duan X; Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, 400016, China.; Zhang L

Subjects: Gastrointestinal Microbiome* ; Noncommunicable Diseases* ; Glucagon-Like Peptides*

  • Source: European journal of pharmacology [Eur J Pharmacol] 2024 Apr 15; Vol. 969, pp. 176440. Date of Electronic Publication: 2024 Feb 24.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.

  • Authors : Zeng H; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, PR China.; Song J

Subjects: Lactic Acid*/Lactic Acid*/Lactic Acid*/chemistry ; Polyglycolic Acid*/Polyglycolic Acid*/Polyglycolic Acid*/chemistry ; Glucagon-Like Peptides*

  • Source: International journal of pharmaceutics [Int J Pharm] 2024 Apr 10; Vol. 654, pp. 123991. Date of Electronic Publication: 2024 Mar 11.Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

  • Authors : Tobaiqy M; Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. .; Elkout H

Subjects: Liraglutide*/Liraglutide*/Liraglutide*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-2 Receptor*

  • Source: International journal of clinical pharmacy [Int J Clin Pharm] 2024 Apr; Vol. 46 (2), pp. 488-495. Date of Electronic Publication: 2024 Jan 24.Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Semaglutide: A New Medical Swiss Army Knife?

Subjects: Glucagon-Like Peptides*; Humans

  • Source: Journal of cardiothoracic and vascular anesthesia [J Cardiothorac Vasc Anesth] 2024 Apr; Vol. 38 (4), pp. 871-873. Date of Electronic Publication: 2023 Dec 25.Publisher: W.B. Saunders Country of Publication: United States NLM ID: 9110208 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.

  • Authors : Kral P; IQVIA, Bratislava, Slovakia, IQVIA, Bratislava, Slovakia.; Allen FL

Subjects: Quality of Life* ; Glucagon-Like Peptides*; Humans

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Apr; Vol. 26 (4), pp. 1171-1179. Date of Electronic Publication: 2024 Jan 09.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.

  • Authors : Tong G; Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing, China.; Lu S

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*analogs & derivatives; Humans

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Apr; Vol. 26 (4), pp. 1540-1543. Date of Electronic Publication: 2024 Jan 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.

  • Authors : Davidy T; The Joseph Sagol Neuroscience, Center Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel; Department of Neurology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. Electronic address: .

Subjects: Metabolic Syndrome*/Metabolic Syndrome*/Metabolic Syndrome*/drug therapy ; Dementia* ; Cardiovascular Diseases*

  • Source: Mechanisms of ageing and development [Mech Ageing Dev] 2024 Apr; Vol. 218, pp. 111898. Date of Electronic Publication: 2023 Dec 29.Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 0347227 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.

  • Authors : Li Y; Department of Emergency Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.; Gong X

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/analogs & derivatives ; Immunoglobulin Fc Fragments*

  • Source: European journal of clinical investigation [Eur J Clin Invest] 2024 Apr; Vol. 54 (4), pp. e14125. Date of Electronic Publication: 2023 Nov 11.Publisher: Wiley Country of Publication: England NLM ID: 0245331 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2362

Record details

×
Academic Journal

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY 3-36 , and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.

  • Authors : Kloock S; Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Germany.; Haerting N

Subjects: Receptors, Neuropeptide Y*/Receptors, Neuropeptide Y*/Receptors, Neuropeptide Y*/metabolism ; Fatty Liver*/Fatty Liver*/Fatty Liver*/drug therapy ; Fatty Liver*/Fatty Liver*/Fatty Liver*/etiology

  • Source: Nutrients [Nutrients] 2024 Mar 21; Vol. 16 (6). Date of Electronic Publication: 2024 Mar 21.Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.

  • Authors : Ganeshalingam AA; Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, Odense Universitetshospital, Odense, Denmark .; Department of Internal Medicine, Lillebaelt Hospital - University Hospital of Southern Denmark, Kolding, Denmark.

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use ; Prediabetic State*/Prediabetic State*/Prediabetic State*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications

  • Source: BMJ open [BMJ Open] 2024 Mar 18; Vol. 14 (3), pp. e077173. Date of Electronic Publication: 2024 Mar 18.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  9,882 results for ""Glucagon-Like Peptides""